Helicobacter pylori: Clinical aspects

Journal of Infection

Volumn 34, Issue 1, 1997, Pages 7-13

  McColl, K E L ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE;

CLINICAL FEATURE; DIARRHEA; GRAM NEGATIVE INFECTION; HEADACHE; HELICOBACTER PYLORI; NAUSEA; PSEUDOMEMBRANOUS COLITIS; SHORT SURVEY;

EID: 0031039125     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(97)80003-5     Document Type: Article

References (61)

1. Graham DY, Malaty HM, Evans DG, Evans D Jr, Klein PD, Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Gastroenterology 1991; 100: 1495-1501.
2. Hook-Nikanne J, Sistonen P, Kosunen TU. Effect of ABO blood group and secretor status on the frequency of Helicobacter pylori antibodies. Scand J Gastroenterol 1990; 25: 815-818.
3. Cullen DJE, Collins BJ, Christiansen KJ et al. When is Helicobacter pylori infection acquired? Gut 1993; 34: 1681-1682.
4. Mitchell HM, Li YY, Hu PJ et al. Epidemiology of Helicobacter pylori in Southern China: Identification of early childhood as the critical period for acquisition. J Infect Dis 1992; 166: 149-153.
5. Holcombe C. Helicobacter pylori: the African enigma. Gut 1992; 33: 429-431.
6. Sullivan PB, Thomas JE, Wight DGD et al. Helicobacter pylori in Gambian children with chronic diarrhoea and malnutrition. Arch Dis Child 1990; 65: 189-191.
7. Veldhuyzen van Zanten SJO, Pollak PT, Best LM, Bezanson GS, Marrie T. Increasing prevalence of Helicobacter pylori infection with age: continuous risk of infection in adults rather than cohort effect. J Infect Dis 1994; 169: 434-437.
8. Kosunen TU, Hook J, Rautelin HI, Myllyla G. Age-dependent increase of Helicobacter pylori antibodies in blood donors. Scand J Gastroenterol 1989; 24: 110-114.
9. Kelly SM, Pitcher MCL, Farmery SM, Gibson GR. Isolation of Helicobacter pylori from faeces of patients with dyspepsia in the United Kingdom. Gastroenterology 1994; 107: 1671-1674.
10. Bayerdorffer E, Lehn N, Hatz R et al. Difference in expression of Helicobacter pylori gastritis in antrum and body. Gastroenterology 1992; 102: 1575-1582.
11. Fiocca R, Villani L, Luinetti O et al. Helicobacter pylori colonisation and histopathological profile of chronic gastritis in patients with or without dyspepsia, mucosal erosion and peptic ulcer: A morphological approach to the study of ulcerogenesis in man. Virchows Archiv A Pathol Anat 1992; 420: 489-498.
12. Rauws EA, Langenberg W, Houthoff HJ, Zanen HC, Tytgat GN. Campylobacter pyloridis-associated chronic active antral gastritis. A Prospective Study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 1988; 94: 33-40.
13. Johnston BJ, Reed PI, Ali MH. Campylobacter like organisms in duodenal and antral endoscopi biopsies: relationships to inflammation. Gut 1986; 27: 1132-1137.
14. Satoh K, Kimura K, Yoshida Y, Kasano T, Kihira K, Taniguchi Y. Relationship between Helicobacter pylori colonisation and acute inflammation of the duodenal mucosa. Am J Gastroenterol 1993; 88: 360-363.
15. Mobley HLT, Cortesia MJ, Rosenthal LE, Jones BD. Characterization of urease from Campylobacter pylori. J Clin Microbiol 1988; 26: 831-836.
16. Neithercut WD, Milne A, Chittajallu RS, Nujumi AM El, McColl KEL. Detection of Helicobacter pylori infection of the gastric mucosa by measurement of gastric aspirate ammonium and urea concentrations. Gut 1991; 32: 973-976.
17. Marshall BJ, Barrett LJ, Prakash C, McCallum RW, Guerrant RL. Urea protects Helicobacter (Campylobacter) pylori from the bactericidal effect of acid. Gastroenterology 1990; 99: 697-702.
18. McColl KEL, El-Nujumi AM, Chittajallu RS et al. A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. Gut 1993; 34: 762-768.
19. Hentschel E, Brandstatter G, Dragosics B et al. Effect of ranitidine and amoxycillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 308-312.
20. Tatsuta M, Ishikawa H, Ishi H, Okuda S, Yokota Y. Reduction of gastric ulcer recurrence after suppression of Helicobacter pylori by cefixime. Gut 1990; 31: 973-976.
21. Hosking SW, Ling TK, Chung SCS et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet 1994; 343: 508-510.
22. Forbes GM, Glaser ME, Cullen DJ et al. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow up. Lancet 1994; 343: 258-260.
23. Marshall BJ, Goodwin CS, Warren JR et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; 1437-1441.
24. McColl KEL, Fullarton GM, Chittajallu R et al. Plasma gastrin, daytime intragastric pH, and nocturnal acid output before and at 1 and 7 months after eradication of Helicobacter pylori in duodenal ulcer subjects. Scand J Gastroenterol 1991; 26: 339-346.
25. Graham DY, Opekum A, Lew GM, Evans DJ, Klein PD, Evans DG. Ablation of exaggerated meal-stimulated gastrin release in duodenal ulcer patients after clearance of Helicobacter (Campylobacter) pylori infection. Am J Gastroenterol 1990; 85: 394-398.
26. Levi S, Beardshall K, Haddad G, Playford R, Ghosh P, Calam J. Campylocobacter pylori and duodenal ulcers: The gastrin link. Lancet 1989: 1167-1168.
27. 7 Moss SF, Legon S, Bishop AE, Polak JM, Calam J. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 1992; 340: 930-932.
28. Kaneko H, Nakada K, Mitsuma T et al. Helicobacter pylori infection induces a decrease in immunoreactive-somatostatin concentrations of human stomach. Dig Dis Sci 1992; 37: 409-416.
29. Queiroz DMM, Mendes EN, Rocha GA et al. Effect of Helicobacter pylori eradication on antral gastrin- and somatostatin-immunoreactive cell density and gastrin and somatostatin concentrations. Scand J Gastroenterol 1993; 28: 858-864.
30. Moss SF, Calam J. Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of Helicobacter pylori. Gut 1993; 34: 888-892.
31. El-Omar E, Penman ID, Ardill JES, Chittajallu RS, Howie C, McColl KEL. Helicobacter pylori and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109: 681-691.
32. Gillen D, El-Omar E, McColl KEL. Parietal sensitivity to gastrin distinguishes H. pylori infected DU patients from infected healthy volunteers. Gut 1995; 37 (Suppl. 1): A8.
33. McColl KEL, El-Omar E, El-Nujumi A, Wirz A, Covacci A, Crabtree JE. H. pylori-induced hypergastrinaemia is related to bacterial CagA status. Gastroenterology (in press).
34. Numura A, Stemmermann GN, Chyou P-H, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and the risk of duodenal and gastric ulceration. Ann Intern Med 1994; 120: 977-981.
35. Sung JY, Chung SC, Ling TKW et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995; 332: 139-142.
36. Labenz J, Borsch G. Evidence for the essential role of Helicobacter pylori in gastric ulcer disease. Gut 1994; 35: 19-22.
37. Parsonnet J, Friedman GD, Vandersteen DP et al. Helicobacter pylori and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-1131.
38. Forman D, Newell DG, Fullerton F et al. Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation. Br Med J 302: 1302-1305.
39. Hansson LE, Engstrand L, Nyren O et al. Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma. Gastroenterology 1993; 105: 1098-1103.
40. Correa P, Fox J, Fontham E et al. Helicobacter pylori and gastric carcinoma. Serum antibody prevalence in populations with contrasting cancer risks. Cancer 1990; 66: 2569-2573.
41. Eurogast Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993; 341: 1359-1362.
42. Sobala GM, Schorah CJ, Lynch DAF, Gallacher B, Dixon MF, Axon ATR. Effect of eradication of Helicobacter pylori on gastric juice ascorbic acid concentrations. Gut 1993; 34: 1038-1041.
43. Banerjee S, Hawksby C, Miller S, Dahill S, Beattie AD, McColl KEL. Effect of Helicobacter pylori and its eradication on gastric juice ascorbic acid. Gut 1994; 35: 317-322.
44. Sobala GM, Pignatelli B, Schorah CJ et al. Levels of nitrite, nitrate, N-nitroso compounds, ascorbic acid and total bile acids in gastric juice of patients with and without precancerous conditions of the stomach. Carcinogenesis 1991; 12: 193-198.
45. Comfort MW, Kelsey MP, Berkson J. Gastric acidity before and after the development of carcinoma of the stomach. J Natl Cancer Inst 1947; 7: 367-373.
46. Hill MJ. Bacterial N-nitrosation and gastric carcinogenesis in humans. Ital J Gastroenterol 1991; 23: 17-23.
47. El-Omar E, Wirz A, McColl KEL. Divergent effects of H. pylori on acid secretion. Gut 1995; 37: A82.
48. Tucci A, Poli L, Paparo GF et al. Effect of Helicobacter pylori (HP) eradication in patients with fundic atrophic gastritis. Gut 1994; 35 (Suppl. 4): 1514.
49. Yasunaga Y, Shinomura Y, Ka nayama S et al. Improved fold width and increased acid secretion after eradication of the organism in Helicobacter pylori associated fold gastritis. Gut 1994; 35: 1571-1574.
50. Bayderdorffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S, Stolte M, for MALT Lymphoma Study Group. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet 1995; 345: 1591-1594.
51. Hussell T, Isaacson PG, Crabtree JE, Spencer J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 1993; 342: 571-574.
52. Tytgat GNJ. Review article: treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994; 8: 359-368.
53. Penston JG. Review article: Helicobacter pylori eradication - understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994; 8: 369-389.
54. Chiba N, Rao BV, Rademaker JW, Hunt R. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992; 87: 1716-1727.
55. Bell GD, Powell KU, Burridge SM. Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9: 41-46.
56. Ali-assi MT, Ramirez FC, Lew GM, Genta RM, Graham DY. Clarithromycin tetracycline, and bismuth: A new non-metronidazole therapy for Helicobacter pylori infection. Am J Gastroenterol 1994; 89: 1203-1205.
57. Thijs JC, Van Zwet AA, Oey HB. Efficacy and side effects of a triple drug regimen for the eradication of Helicobacter pylori. Scand J Gastroenterol 1993; 28: 934-938.
58. Unge P, Gad A, Gnarpe H, Olsson J. Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? A pilot study. Scand J Gastroenterol 1989; 24 (Suppl. 167): 49-54.
59. Biasco G, Miglioli M, Barbara L, Corinaldesi R, Di Febo G. Omepraxole. Helicobacter pylori, gastritis and duodenal ulcer. Lancet: 1403.
60. Bell GD, Powell KU, Burridge SM. Reinfection or recrudescence after apparently successful eradication of Helicobacter pylori infection: implications for treatment of patients with duodenal ulcer disease. Q J Med 1993; 86: 375-382.
61. Czinn SJ, Nedrud JG. Oral immunization against Helicobacter pylori. Infect Immun 1991; 59: 2359-2363.